Latest Trials Latest NewsFAQ

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2017-11-09

Last Posted Date: 2024-03-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 579

Registration Number: NCT03337724

Locations: 🇩🇪
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany
🇺🇸
Kaiser Permanente - Roseville, Roseville, California, United States
🇺🇸
Kaiser Permanente - South San Francisco, South San Francisco, California, United States

and more 173 locations

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab
Drug: Docetaxel
Drug: RO6958688
Drug: CPI-444
Drug: Linagliptin
Drug: Sacituzumab Govitecan
Drug: Bevacizumab
Drug: Camonsertib
Drug: Cobimetinib
Drug: Ipatasertib
Drug: Pemetrexed
Drug: Evolocumab
Drug: Tiragolumab
Other: Radiation
Drug: Tocilizumab
Drug: Carboplatin
Drug: Gemcitabine
Drug: XL092

First Posted Date: 2017-11-09

Last Posted Date: 2024-12-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 314

Registration Number: NCT03337698

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳
National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan

and more 33 locations

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

Phase 4

Completed

Conditions: Neoplasms

Interventions: Procedure: Biopsy

First Posted Date: 2017-11-07

Last Posted Date: 2022-08-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT03333655

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UCSF Comp Canc Ctr, San Francisco, California, United States
🇺🇸
Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, United States

and more 8 locations

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Completed

Conditions: Urothelial Carcinoma

First Posted Date: 2017-11-06

Last Posted Date: 2023-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 13

Registration Number: NCT03330886

Locations: 🇦🇷
Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires, Argentina

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: Entrectinib
Drug: Midazolam Hydrochloride

First Posted Date: 2017-11-06

Last Posted Date: 2018-08-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT03330990

Locations: 🇺🇸
SCRI-Denver Drug Development Program, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

Completed

Conditions: Carcinoma, Non-small-cell Lung

First Posted Date: 2017-10-26

Last Posted Date: 2023-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 44

Registration Number: NCT03321695

Locations: 🇦🇷
Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires, Argentina

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

Phase 3

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2017-10-20

Last Posted Date: 2024-12-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 85

Registration Number: NCT03315455

Locations: 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing City, China
🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China
🇭🇰
Queen Mary Hospital, Hong kong, Hong Kong

and more 10 locations

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cobimetinib
Drug: Atezolizumab
Drug: Venetoclax

First Posted Date: 2017-10-17

Last Posted Date: 2023-02-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT03312530

Locations: 🇫🇷
CHU - Hôtel Dieu hematolgie clinique, Nantes, France
🇨🇿
Fakultni nemocnice Ostrava; Klinika hematoonkologie, Ostrava, Czechia
🇨🇿
Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia

and more 23 locations

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 4

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab
Drug: NSAIDs
Drug: CSs
Drug: MTX

First Posted Date: 2017-10-04

Last Posted Date: 2024-01-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 62

Registration Number: NCT03301883

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳
Shanghai Children's Medical Center; Renal rheumatology, Shanghai City, China
🇨🇳
Capital Institute of Pediatrics, Beijing City, China

and more 7 locations

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Glaucoma, Open-angle
Ocular Hypertension

Interventions: Drug: 0.01% RO7058584
Drug: 1% RO7058584
Drug: Matching Placebo
Drug: 0.1% RO7058584
Drug: Latanoprost 0.005%

First Posted Date: 2017-09-26

Last Posted Date: 2020-03-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 27

Registration Number: NCT03293992

Locations: 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸
Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow, Georgia, United States
🇺🇸
Rocky Mountain Lions Eye Inst, Aurora, Colorado, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy